BCR-ABL1 Compound Mutations Combining Key Kinase Domain Positions Confer Clinical Resistance to Ponatinib in Ph Chromosome-Positive LeukemiaMatthew S. Zabriskie, Thomas O’Hare, Hagop M. Kantarjian et al.|Cancer Cell|2014Cited by 366
Observation versus antiplatelet therapy as primary prophylaxis for thrombosis in low-risk essential thrombocythemiaAlberto Álvarez‐Larrán, Carlos Besses, Francisco Cervantes et al.|Blood|2010Cited by 233
Assessment and prognostic value of the European LeukemiaNet criteria for clinicohematologic response, resistance, and intolerance to hydroxyurea in polycythemia veraAlberto Álvarez‐Larrán, Carles Besses, Arturo Pereira et al.|Blood|2011Cited by 225
Axicabtagene ciloleucel compared to tisagenlecleucel for the treatment of aggressive B-cell lymphomaMi Kwon, Pere Barba, Gloria Iacoboni et al.|Haematologica|2022Cited by 131
Pemigatinib for Myeloid/Lymphoid Neoplasms with <i>FGFR1</i> RearrangementSrđan Verstovšek, Jason Gotlib, Jean‐Jacques Kiladjian et al.|NEJM Evidence|2025Cited by 7